Syntara Limited

Health Check: Drug developers slug some home runs in their mid-stage studies | Syntara Media coverage by @newscomauHQ news.com.au/finance/business… $SNT #Syntara #ASX #SNT #SNT4728 #ParkinsonsDisease #iRBD #Neuroinflammation #ClinicalResearch

Parkinson's trial shows potential disease halt | Syntara coverage: Podcast by @abcnews listen. abc.net.au/listen/programs/w… $SNT #Syntara #ASX #SNT #SNT4728 #ParkinsonsDisease #iRBD #Neuroinflammation #ClinicalResearch

A simple daily pill could stop Parkinson's disease before it starts | $SNT Media coverage @7NewsAustralia 7news.com.au/lifestyle/healt… #Syntara #ASX #SNT #SNT4728 #ParkinsonsDisease #iRBD #Neuroinflammation #ClinicalResearch

Investor Presentation: Canaccord Drug & Device Conference View the full $SNT Presentation here: cdn-api.markitdigital.com/ap…

Australian trial offers hope in preventing Parkinson’s disease | Syntara media coverage Nine. nine.com.au/australia-news/m… $SNT #ASX #SNT #DrugDevelopment #Biotech #ClinicalTrials

Syntara CEO Gary Phillips will be attending the Drug & Device Conference, hosted by Canaccord Genuity Australia, in Noosa on 12–13 October 2026. With recent positive clinical results from SNT-4728, progress across our skin scarring program and the FDA-supported Phase 2b development pathway for amsulostat, Gary will discuss the latest developments across our clinical-stage pipeline and the key milestones ahead. $SNT #ASX #SNT #CanaccordGenuity #DrugDevelopment #Biotech #Healthcare

Syntara drug candidate slows motor decline in people at high risk of Parkinson's | $SNT Media coverage by @AusBiotech. biotechdispatch.com.au/news/… #SNT #Syntara #Parksinsons

Syntara’s SNT-4728 Parkinson’s research has been featured in The Sydney Morning Herald today, following the release of further positive results from our Phase 2 study in people with iRBD. The article explores the research and the potential of SNT-4728 to target neuroinflammation in people at high risk of developing Parkinson’s Disease. The latest results showed a statistically significant improvement in clinician-assessed motor signs for SNT-4728 versus placebo at Week 24, complementing the previously reported statistically significant reduction in brain inflammation. It’s great to see this important research and the work of our clinical collaborators reaching a broader audience. smh.com.au/national/nsw/abso… #ASX $SNT #SNT4728 #ParkinsonsDisease #iRBD #Neuroinflammation #ClinicalResearch @ParkinsonsUK @Macquarie_Uni

We’ve seen further positive data from our Phase 2 study of SNT-4728 in patients with isolated REM Sleep Behaviour Disorder (iRBD). CEO Gary Phillips discusses the secondary endpoints and the converging evidence of biological activity in reducing neuroinflammation together with improvements in clinician-assessed motor function. The difference between SNT-4728 and placebo in clinician-assessed motor signs was statistically significant at Week 24, three months after treatment ceased. Together with the previously reported reduction in neuroinflammation, the results support the potential for SNT-4728 as a disease-modifying therapy in prodromal and early Parkinson’s Disease. Watch Gary’s update below. Read the full $SNT Announcement here: cdn-api.markitdigital.com/ap… #Syntara #ASX #SNT #SNT4728 #ParkinsonsDisease #iRBD #Neuroinflammation #ClinicalTrials

We’ve seen a statistically significant improvement in clinician-assessed motor signs for SNT-4728 versus placebo at Week 24, 12 weeks after completion of treatment. These results complement the previously reported statistically significant reduction in brain inflammation, with converging evidence of biological activity and improvement in motor function supporting further clinical development of SNT-4728 as a potential disease-modifying therapy in prodromal and early Parkinson’s Disease. Results will be presented by Principal Investigator Professor Simon Lewis today at the International Congress of Parkinson’s Disease and Movement Disorders in Seoul, South Korea. Read more: cdn-api.markitdigital.com/ap… $SNT #SNT4728 #ParkinsonsDisease #iRBD #Neuroinflammation #ClinicalDevelopment

Syntara expands scar trial as earlier compound causes skin reactions | $SNT Media coverage by @AusBiotech biotechdispatch.com.au/news/… #SNT #Syntara #Biotech

Syntara Expands Safety and Tolerability Study of SNT-9465 Topical Scar Treatment | $SNT Media coverage by @SmallCapsASX. smallcaps.com.au/article/syn… #SNT #Syntara #Biotech

Syntara Expands Scar Drug Trial to 30 Patients With Results Due Q1 2027 | $SNT Media coverage by @StockWireX stockwirex.com/asx-stock-new…

We’ve expanded our SNT-9465 Phase 1b study in hypertrophic sternotomy scars from 20 to 30 participants. In this update, $SNT CEO Gary Phillips explains the background to today’s announcement, including why we’ve maintained the blinded study design while increasing participant numbers to provide a larger and more robust dataset. The Skin Hospital in Sydney has also been added as an additional clinical site, with top-line results expected in Q1 2027. Watch Gary’s update below. #Syntara #ASX #SNT #SNT9465 #SkinScarring #ClinicalTrials #PanLOX #DrugDevelopment

We’ve expanded our SNT-9465 Phase 1b study in hypertrophic sternotomy scars from 20 to 30 participants, with the blinded design maintained to support a larger and robust dataset. The Skin Hospital, Sydney, has been added as an additional clinical site to support timely recruitment of the expanded cohort. Top-line results are expected in Q1 2027. CEO Gary Phillips said, “We are pleased with the strong engagement from participants and clinical sites in the SNT-9465 Phase 1b study. This has supported our decision to expand recruitment from 20 to 30 participants to ensure we capture the maximum learnings, while maintaining the study’s blinded design. “Expanding the study at this stage is very cost effective and will deliver more robust results in Q1 2027. Hypertrophic scarring remains an area of significant unmet need, and we look forward to evaluating whether the biological rationale for pan-LOX inhibition translates into an acceptable safety and tolerability profile and evidence of clinical activity in this study.” Read the full $SNT #ASX Announcement here: cdn-api.markitdigital.com/ap… #SNT #SNT9465 #SkinScarring #ClinicalStudy #HypertrophicScars #PanLOX

A new @StockWireX article takes a closer look at the design of our Phase 1b study of $SNT-9465 in hypertrophic scarring and why we have chosen a split-scar approach. Each patient acts as their own control, with SNT-9465 and placebo applied to different sections of the same sternotomy scar. This allows us to directly compare treatment and placebo while reducing the biological variability that can make skin scarring studies difficult to assess. With recruitment progressing and results expected this year, it’s a good explanation of why the design of this study matters and what we are looking to demonstrate. Read the StockWire X article: stockwirex.com/education/cli… #Syntara #ASX #SNT #SNT9465 #SkinScarring #ClinicalTrials #Biotech #Fibrosis #DrugDevelopment

We’ve received our R&D tax incentive of A$4.7 million for eligible activities conducted during the 2026 financial year. Read the full $SNT ASX Announcement here: cdn-api.markitdigital.com/ap…

SNT-4728 continues to generate interest following the release of top-line results from our Phase 2 study in patients with isolated REM Sleep Behaviour Disorder (iRBD). Syntara CEO Gary Phillips discusses the positive reaction from the Parkinson’s community and the upcoming plenary presentation of the study at the Global Movement Disorders Symposium in Seoul. With further results expected in the coming months, including biomarkers, wearable device data and assessments of sleep, we expect to gain a deeper understanding of the impact of SNT-4728 on disease pathology. $SNT #SNT4728 #ParkinsonsDisease #iRBD #Neuroinflammation #ClinicalTrials #DrugDevelopment

“The key to the value in our skin scarring program is the design of the current hypertrophic scar study.” CEO Gary Phillips provides an update on the progress of our skin scarring program and the Phase 1b study of second-generation topical pan-LOX inhibitor SNT-9465. The study uses each patient as their own control, allowing active treatment and placebo to be directly compared on the same sternotomy scar, with endpoints assessing changes in scar pliability, height and volume. With the study 60% recruited in July, full recruitment is expected by the end of the quarter and results by the end of the year. Watch the full $SNT update here: youtu.be/JrxOEwFZWH0?si=YkLP… #Syntara #ASX #SNT #SNT4728 #ParkinsonsDisease #iRBD #Neuroinflammation #ClinicalTrials #DrugDevelopment